Kunena :: Тема: Posted by Allison on 30.11.2016 13:37:14: tarceva egfr survival (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Allison on 30.11.2016 13:37:14: tarceva egfr survival

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Allison on 30.11.2016 13:37:14: tarceva egfr survival

Страница:
1
2

ТЕМА: Posted by Allison on 30.11.2016 13:37:14: tarceva egfr survival

Posted by Allison on 30.11.2016 13:37:14: tarceva egfr survival 7 года 5 мес. назад #943

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
merci josinette pour tes reponses,et je poserais des questions au cancerologue.je croise les doigts pour ton scann de mardi,au fait comment sont tes resultats depuis ta prise de tarceva? mon mari prends tarceva que depuis le 17 septembre,on lui a fait un scann au bout de 3 semaines et les 2 nodules etaient stables donc maintenant esperons que debut decembre ils auront un peu diminues ou au moins seront stabilises.c'est toujours la hantise avant les examens.bon courage et a plus.
Experimental: Tarceva and FOLFOX
test1.saitrus.ru/kunena/razdel-predlozhe...7-48-erlotinib-sales
Determine the time to progression in patients with locally advanced squamous cell carcinoma of the head and neck treated with erlotinib hydrochloride in combination with docetaxel and radiotherapy.
We are counted among the leading Exporters and Suppliers of Erlonat Tablets. Drug Name. Erlotinib Types of Diseases. Lung Cancer Uses.
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Co-treatment with MPT0E028 and erlotinib suppresses the growth of erlotinib-resistant tumor xenografts in vivo
biozona.com.ua/forum/6/25933-posted-by-j...xchange-program.html
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
The serum concentration of Erlotinib can be decreased when it is combined with Fosphenytoin.
Figure 2. Mass spectra of erlotinib ( A ) and erlotinib- d 6 ( B ) and their fragmentation pathways.
We excluded any study using other concurrent cancer therapy with erlotinib; studies that did not have EGFRWT data or Phase II randomized studies.
Erlotinib therapy was also associated with more nausea (33% vs 24%) and vomiting (23% vs 19%). Three erlotinib-treated patients developed Grade 3 renal insufficiency compared with none of the placebo-treated patients. As per the sponsor, each patient had confounding comorbidities that were likely to have caused impairment rather than a direct nephrotoxic effect. However, it is noted in the non-clinical review, that Tarceva ® can have a direct nephrotoxic effect (renal papillary necrosis and tubular dilatation were seen in animal studies). It will be important to be vigilant regarding renal toxicity.
bowlangarsk.ru/forum/otchety-i-obsuzhden...eva-roche-prospektüs
The study also demonstrated that patients who received docetaxel experienced a longer survival than those who received erlotinib. This association was independent of KRAS mutation status.
www.topdach.com.ua/component/kunena/post?Itemid=0
Celebrex-Tarceva Duo 'Promising' in Late-Stage Lung Cancer Trial
Nuestra serie (tabla 1 ) se compone de 20 varones y 20 mujeres caucásicos de 38-80 años. Trece eran fumadores, 2 fumaban menos de 5 cigarrillos/día, 7 eran exfumadores y 20 nunca habían fumado. Las muestras eran 12 biopsias en parafina, 14 botones celulares obtenidos por punción-aspiración con aguja fina (PAAF) y conservados en parafina y 14 citologías obtenidas por PAAF. Poseíamos 5 carcinomas escamosos, 23 ADC, 4 ADC con carcinoma bronquioloalveolar (BAC) y 8 NSCLC sin especificar. Se desconocía el estatus EGFR de 6 muestras, 23 poseían EGFR nativo y 11 mutaciones sensibilizadoras: 9 e19(p.746-750del), 1 e19(L747-A750del PIns), 1 e19(L746-A752del VIns), 1 e19(c.2240-2257del), 1 e18 (p.G719R), 1 e18(E709A; G719R), 1 e18(E709G) y e21(L858R) y 1 e21(L858R). No se detectaron mutaciones de resistencia 2 . Recibieron erlotinib, otro EGFR-TKI más efectivo sobre EGFR mutado, 28 casos.
His group reviewed the results of an open-label, phase III clinical trial performed in France, Italy, and Spain that compared first-line therapy with erlotinib versus standard chemotherapy in patients with EGFR-mutated NSCLC. The primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival and tolerability.
The LUX-Lung 3 study is one of the first in which people with lung cancer and EGFR gene mutations received afatinib. Researchers are encouraged by the fact that afatinib was more effective than the combination of two chemotherapy drugs used most often for this type of cancer. Approximately 38,000 Americans are diagnosed with EGFR mutation-positive lung cancer each year. In the near future, afatinib may be an effective treatment alternative for these people. Similar studies have previously been presented with the drugs erlotinib and gefitinib. In all of these trials, the results have been similar: Compared with chemotherapy, the treatments that target EGFR gene mutations were more effective in destroying the tumor and increasing the time before the tumor grew again. However, starting with chemotherapy first and then switching to the EGFR-targeted drug later is also an effective strategy. If the EGFR gene mutation status is not known, it is better to start with chemotherapy.
Example 2D: Process for the preparation of erlotinib maleate monohydrate
www.neodatavalle.com.mx/profiles/blogs/p...9-54-04-erlotinib-in
Brain metastases (BM) are a common and lethal complication of non-small cell lung cancer (NSCLC) with up to 40% experiencing this complication. The use of erlotinib, a small molecule epidermal growth.
Erlotinib has been shown to be a potent inhibitor of JAK2-V617F, a mutant of tyrosine kinase JAK2 found in a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia and most patients with polycythemia vera (PV). The study indicates that erlotinib may be used to treat JAK2-V617F-positive PV and other myeloproliferative disorders. Li, Z. et al. "Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth." J. Biol. Chem. 282: 3428-3432 (2007).
Chemotherapy /- erlotinib (TARCEVA) v placebo
ea-me.de/index.php?do=/blog/63209/posted...-tarceva-effets-sec/
Insuficiencia hepática: No se han estudiado la seguridad ni la eficacia de TARCEVA en pacientes con insuficiencia hepática. El erlotinib se elimina por metabolismo hepático y excreción biliar. Por tanto, se debe proceder con cuidado cuando se administre TARCEVA a pacientes con insuficiencia hepática (ver farmacocinética).
www.sbreader.com/index.php/forum/razdel-...tarceva-ontario.html
I just made a bunch of posts and this slipped down the list. I wanted to bump it back up for others to read. I, personally, feel this is an important topic. I read some and will finish later. When I first came back to this forum this year, I searched Tarceva and this is the thread I found, lacking today's posts, of course. (grin)
All patients will receive erlotinib at 150mg orally daily along with doses of ruxolitinib orally twice daily. Patients in dose level 1 will receive erlotinib 150mg orally daily and ruxolitinib 10mg orally twice daily. In dose level 2, patients will receive erlotinib 150mg orally daily and ruxolitinib 15mg orally twice daily. In dose level 3, patients will receive erlotinib 150mg orally daily and ruxolitinib 20mg orally twice daily.